Integrin Inhibitors as a Therapeutic Agent for Ovarian Cancer

Table 1

Candidate integrin inhibitors for ovarian cancer treatment.

Drug name	Type	Target	Preclinical data in gynecologic cancer	Manufacturer	Ref.
Volociximab (M200)	Chimeric antibody	α5β1	i.p. treatment reduced tumor burden and ascites in SKOV-3ip1 ovarian cancer mouse xenografts by 83% and 97%, respectively.	Protein Design Labs	[20]
ATN-161	Peptide	α5β1	i.v. (1 mg/kg) injection inhibited the outgrowth of metastases at lung, liver, or spleen in a metastasis model mouse of MDA-MB-231 breast cancer cell lines.	Attenuon LLC	[28]
Etaracizumab (MEDI-522)	Humanized antibody	αvβ3	i.p. treatment decreased tumor burden in the SKOV3ip1 and the HeyA8 mouse models by 36 and 49%, respectively and reduced the number of proliferating cells but not microvessel density.	Medimmune	[29]
Intetumumab (CNTO95)	Human antibody	αvβ3 αvβ5	Low doses (0.15–1.25 μg/mL) of intetumumab were effective in inhibiting adhesion and migration of 6 uterine serous papillary carcinoma cell lines in vitro.	Centocor	[30]
Cilengitide (EMD-121974)	Peptide	αvβ3 αvβ5	αvβ3-integrin overexpression on SKOV3ip1 cells impaired invasion, protease expression, and colony formation in vitro. Cilengitide may have detrimental effects against ovarian cancer.	Merck KGaA	[26]